Identification of 55 patients with stage IV melanoma with APC/CTNNB1 genetic aberrations allowed us to understand their role in predicting response to immunotherapies more robustly than the eight, stage IV patients with APC/CTNNB1 somatic mutations from the TCGA SKCM cohort. This evidence concerns the gene APC and melanoma.